Shafer David Brent Acquires Veracyte Shares

Insider buying at Veracyte sees Shafer David Brent acquiring 5,272 shares.

Written by EarningsIQ · Published Jun 15, 2026, 5:05 PM EDT

Key Points

Shafer David Brent purchased 5,272 shares of Veracyte, Inc. on June 11, 2026, at no cost per share.
Veracyte, Inc. trades on NasdaqGM under the ticker VCYT, with a current stock price of $47.33.
Analyst ratings from Needham and UBS maintain a 'buy' with price targets of $57 and $52, respectively.

Shafer David Brent recently bought 5,272 shares of Veracyte, Inc. (NasdaqGM: VCYT) on June 11, 2026. The transaction was recorded at no cost per share, highlighting insider confidence in the company's prospects.

What Changed in Shafer David Brent's Veracyte Position

Shafer David Brent's purchase of 5,272 shares of Veracyte is a notable move in the company's insider trading activity. This acquisition, completed without any direct payment for the shares, suggests a strategic interest in Veracyte's future performance.

Other Institutional Activity in Veracyte

Several institutional investors have also adjusted their positions in Veracyte. BlackRock, Inc. increased its holdings by 43,817 shares, ending with 13,172,618 shares valued at approximately $424.3 million. FMR LLC significantly boosted its stake by 2,025,640 shares, reaching a total of 7,763,849 shares worth about $250.1 million. In contrast, Artisan Partners Limited Partnership reduced its holdings by 766,671 shares, resulting in 5,496,370 shares valued at $177 million. State Street Corp added 682,677 shares, bringing its total to 5,043,590 shares with a value of $162.5 million.

Veracyte Stock Snapshot

Shares of Veracyte, Inc. (NasdaqGM: VCYT) are trading around $47.33. The company has a market cap of approximately $3.78 billion and a P/E ratio of 43.82. The stock's 52-week range is between $22.61 and $50.71, with a 50-day moving average of $39.21 and a 200-day moving average of $38.00. Veracyte's beta is 1.98, indicating higher volatility compared to the market. The company maintains a strong balance sheet with a current ratio of 9.31 and a quick ratio of 8.72.

Recent Earnings

Veracyte reported revenue of $541.7 million, showing a growth of 21.5%. The company's net margin stands at 16.25%, with a return on equity of 6.93%. Earnings per share (EPS) is reported at $1.08. The next earnings report is scheduled for August 5, 2026.

Insider Buying and Selling at Veracyte, Inc.

In addition to Shafer David Brent, other insiders such as Barr Eliav, Bhanji Muna, Epstein Robert, Jones Evan/ FA, and Holstein Jens also acquired 5,272 shares each on June 11, 2026. These transactions were not part of any pre-planned trading programs.

Analysts Set New Price Targets

On June 1, 2026, Needham maintained a 'buy' rating for Veracyte with a price target of $57. UBS also maintained its 'buy' rating on May 6, 2026, with a target of $52. The consensus among analysts is a 'buy' recommendation, with a mean target price of $49.10 based on 10 analyst opinions.

About Veracyte, Inc.

Veracyte, Inc., headquartered in South San Francisco, California, operates in the healthcare sector, focusing on diagnostics and research. The company provides genomic tests for various cancers, including thyroid, prostate, bladder, breast, and lung cancers. Their products include the Afirma Genomic Sequencing Classifier and the Decipher Prostate Genomic Classifier, among others. Under the leadership of CEO Marc A. Stapley, Veracyte employs around 755 people and continues to expand its diagnostic capabilities both in the U.S. and internationally.

Bottom Line

The recent insider buying activity at Veracyte, Inc. reflects confidence from key stakeholders, including Shafer David Brent. Investors closely monitor insider transactions as potential indicators of a company's future performance. While insider buying can signal positive sentiment, it is essential to consider these actions in the broader context of market conditions and company fundamentals.